News
Reinnervate partners with LGC for global distribution of alvetex®
29 / 11 / 2010
Sedgefield, UK. 29th November 2010. Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, is delighted to announce that it is partnering with LGC Standards for the non-exclusive distribution and sale of alvetex®, its breakthrough 3D cell culture technology. LGC Standards is a division of LGC and a leading supplier of cutting-edge research tools to life science researchers across Europe. The product will be made available for order through the LGC Standards web site www.lgcstandards.com/3D and will also be promoted through a number of LGC Standards product catalogues.
In addition, the companies will be collaborating on the use of alvetex® to generate realistic 3D cell models for drug discovery and development applications. For example, one key area of research has focused on the use of alvetex® to generate liver cell cultures that closely mimic the structure and function of the same cells in the body. An accurate 3D model of the liver can allow researchers to examine the toxicity of new pharmaceuticals and be predictive of the effects of the these drugs in the body, while ultimately reducing the need for animal-based testing.
Data generated by LGC scientists, and funded by the UK’s National Measurement System, demonstrate that liver cells grown in alvetex® produce significantly higher levels of key enzymes involved in drug metabolism and improved responses of the cells to known cytotoxic compounds, than liver cells grown in conventional 2D culture.
Richard Rowling, Commercial Director commented: “The partnership with LGC is a significant milestone for the company as we look to launch alvetex® in a range of standard multi-well formats and well inserts over the next 12 months. Alvetex® is a game-changing technology that has the potential to revolutionise the use and value of cell-based applications in basic and industrial research, and as such is in great demand. In order to meet this demand, reinnervate aims to partner, on a non-exclusive basis, with multiple distributors of life sciences research products around the world and is delighted that LGC has become our first partner.”
Jeffrey Anthony, Biologicals Business Unit Manager at LGC Standards commented: “3D cell culture is widely recognised as offering many advantages to cell biologists by enabling cell behaviour that more effectively mimics in vivo characteristics. The alvetex® product now makes the benefits of 3D culture routinely available to research laboratories across the world and we are delighted to enable access to this important technology in partnership with the scientists at reinnervate.”
About alvetex®
Alvetex® is a unique polystyrene material that provides a robust and inert scaffold for cells to grow and form complex 3D structures in the laboratory, mimicking the normal growth and formation of tissues in the body. Reinnervate has extensively tested and validated alvetex® with a large number of cell types, including liver, skin, cancer and stem cells, all of which have important applications in basic research into cell development, disease modelling and drug safety screening.
Alvetex® has initially been launched in a 12-well culture plate format that is now available through LGC Standards. The alvetex® 12 well plate comes as an off-the-shelf, sterile-packed and ready-to-use product that is expected to revolutionise what cell biologist can achieve using cell culture techniques.
Reinnervate plans, over the next 12-18 months, to introduce alvetex® products in a range of standard multi-well plates including those suitable for high-throughput drug screening, and unique well inserts that enable long-term 3D cell culture over several weeks. Alvetex® has been designed and developed with the needs of cell biologists in mind and will allow researchers in academia and the pharmaceutical and related industries to construct different 3D cell culture models to meet their specific research needs.
For prices and ordering information, please contact LGC Standards (www.lgcstandards.com) via email: cell@lgcstandards.com or tel: +44 (0)20 8943 8489. Alternatively, please contact Reinnervate Customer Services on +44 (0)1740 625529.
For further information, please contact
For reinnervate
Richard Rowling, Commercial Director
+44 (0)191 334 3988
mailto:richard.rowling@reinnervate.com
Mark Swallow / Malcolm Robertson
Citigate Dewe Rogerson
+44 (0)207 638 9571
mark.swallow@citigatedr.co.uk
For LGC
Gavin Dallas +44 (0)20 8943 8491
gavin.dallas@lgc.co.uk
About reinnervate
Reinnervate is an innovative life sciences company dedicated to making routine 3D cell culture a reality for researchers in academia and in the pharmaceutical and related industries.
Reinnervate’s core technology is alvetex®, a unique and proprietary scaffold that enables routine 3D cell culture in the laboratory. Alvetex provides a nanoscale environment that supports genuine homogeneous 3D cell growth. Cells grown using alvetex form complex 3D tissue cultures, which more closely mimic normal in-vivo cell growth and the formation of tissues in the body. The use of alvetex-derived 3D cell cultures can provide researchers with greater insight into how cells behave in the body in response to external factors (such as drug candidates) than is currently possible with existing 2D or other emerging 3D cell culture technologies.
Reinnervate has generated significant data, which have been published extensively in peer-reviewed publications, exemplifying the use of alvetex in a large number of cell types and applications. alvetex is being developed for commercialisation in a range of formats and is due to be launched in 2010.
Reinnervate is also using its cell biology expertise to generate a library of synthetic small molecules that mediate stem cell differentiation in vitro. The first of these small molecules, ec23®, is commercially available and offers the potential for robust and reproducible differentiation of neural cell types.
Reinnervate was founded in 2002 based on the pioneering research of Professor Stefan Przyborski and his lab at Durham University, UK, and is funded by NorthStar Equity Investors (NSEI), management and private investors.
About LGC
LGC (www.lgc.co.uk) is an international science-based company and market leader in analytical, forensic and diagnostic services and reference standards. A progressive and innovative enterprise, LGC operates in socially responsible fields underpinning the safety, health and security of the public and the regulation of industry, for UK government departments and blue chip clients.
LGC operates internationally through four divisions - LGC Forensics, LGC Genomics, LGC Standards and LGC Science & Technology, which includes specialist laboratories delivering contracts for the Department for Business, Innovation and Skills (BIS) and supporting LGC's designated role as the UK's National Measurement Institute for chemical and bioanalytical measurement.
Our operations are extensively accredited to international quality standards such as ISO 17025. With headquarters in Teddington, South West London, the LGC Group employs 1,400 staff in 27 laboratories and centres across Europe and at sites in India and China. Privatised in 1996 and now majority-owned by funds managed by Bridgepoint, LGC was founded almost 170 years ago as the Laboratory of the Government Chemist - a statutory function maintained by LGC today.
About LGC Standards
LGC Standards (www.lgcstandards.com) provides products and services to improve measurement and quality control within the laboratory, and is part of LGC, whose Science & Technology Division acts as the UK National Measurement Institute for chemical and bioanalytical measurements. LGC Standards supplies over 100,000 products, including reference materials, pharmaceutical impurity reference standards, biological standards and reagents, as well as proficiency testing and training in analytical quality. LGC Standards is headquartered in Teddington, Middlesex, UK. Its global centre for excellence in proficiency testing is located in Bury (Greater Manchester). LGC Standards has offices in France, Germany, Italy, Poland, Spain, Sweden, China, Russia and the UK, a joint venture presence in India, and representatives in Brazil, Bulgaria, Czech Republic, Finland, Hungary, Ireland, the Netherlands, Romania and Turkey.
Reinnervate Ltd to be present at the Beatson Cancer…
Reinnervate Ltd will be present at the Beatson Cancer Conference in Glasgow on 10th July 2013. Representatives from Reinnervate will be on hand to present and discus the…
> read more
Reinnervate and Promega to present 3D cell culture…
Reinnervate Ltd and Promega Corp. will present a series of joint seminars on the US West coast in June 2013. Seminars will take place in San Diego (Tuesday 11th June), Seattle (Wednesday…
> read more
3rd Cell-Based Assays event 18th - 19th March 2013,…
Professor Stefan Przyborski, founder and Chief Scientific Officer of Reinnervate will present on Alvetex Technology That Enables Routine 3D Cell Culture, at 2pm on 18th March at ULU University of…
> read more
ELRIG Research & Innovation 19th March 2013
Richard Rowling Commercial Director of Reinnervate will present on Target-based drug activity and post-translational and transcriptional analysis using ex vivo Alvetex®Scaffold three-dimensional…
> read more
Reinnervate to Exhibit at the American Association…
Reinnervate will exhibit at the American Association for Cancer Research, Annual Meeting, 6th – 10th April, at the Walter E, Washington Convention Centre, Washington, DC.
Discover…
3D cell culture firm Reinnervate and specialist Oncology…
3D cell culture firm Reinnervate and specialist Oncology CRO Oncotest GmbH enter collaboration agreement. Oncotest to offer enhanced pre-clinical oncology and cancer research screening services incorporating…
> read more
3D cell culture firm Reinnervate announce the release…
Sedgefield, UK. November 2012 - Market leading 3D cell culture company, Reinnervate Ltd, today announced that it has launched and commenced shipments of Alvetex®Scaffold 96 well plates to customers.
> read more
Reinnervate to Exhibit at the American Society for…
Reinnervate are exhibiting at the American Society for Cell Biology Annual Conference to be held in San Francisco, California. We would be delighted to welcome you at booth 1017-1019 to discuss our…
> read more
New evidence-based 3D cell culture web portal launched…
Sedgefield, UK. October 2012 – Reinnervate Ltd, the developers of Alvetex®Scaffold for 3D cell culture, today announced the launch of a new 3D cell culture portal for scientists in the life…
> read more
Medicyte GmbH and Reinnervate Ltd to collaborate on…
Heidelberg, Germany and Sedgefield, UK. 9th July 2012 - Two market leading companies in the field of cell based assays and predictive toxicology today announced a new product collaboration. Medicyte…
> read more
Top award for 3D cell culture pioneer, Stefan Przyborski,…
Sedgefield, UK. June 2012 – Prof Stefan Przyborski, CSO and founder of Reinnervate Ltd has been recognised with a top award from the Royal Society of Chemistry.
The Rita and John…
Reinnervate and Tecan to develop automated 3D cell…
Sedgefield, UK and Männedorf, Switzerland. 7 June 2012. Reinnervate Ltd and Tecan Trading AG, have signed a co-marketing agreement to develop a range of automated solutions for 3D cell culture,…
> read more
Reinnervate Ltd and Roslin Cellab announce plans to…
Sedgefield, UK. April 2012. Reinnervate Ltd and Roslin Cellab, two leading UK companies in the fields of 3D cell culture and stem cell biology, today announced that they will join…
> read more
Reinnervate Ltd announce Kirkstall Ltd collaboration
Reinnervate (inventors of alvetex®scaffold) and Kirkstall (developers of the Quasi-Vivo® system) today announced that they will collaborate to bring next generation three…
> read more
Reinnervate and Mirus Bio announce collaboration with…
Sedgefield, UK. November 2011. Reinnervate (Sedgefield, UK) and Mirus Bio (Madison, USA) today announced a commercial agreement to launch a new range of products for the transfection…
> read more
Reinnervate Expands its Distribution Network for alvetex®…
Sedgefield, UK. October 2011. Reinnervate, the emerging global leader in the rapidly growing 3D cell culture market, is delighted to announce it has signed agreements with seven new European distributors…
> read more
alvetex® voted one of most technologically…
Sedgefield, UK. 23rd June 2011. Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, is delighted to announce that alvetex®, its breakthrough…
> read more
Reinnervate partners with AMS Biotechnology (Europe)…
Sedgefield, UK. 31 May 2011. Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, is delighted to announce that it is partnering with AMS Biotechnology…
> read more
SelectScience TV interviews Ashley Cooper of Reinnervate…
Ashley Cooper discusses the launch of the second wave of Alvetex® products for 3D cell culture with SelectScience TV. To watch the interview and learn how Alvetex® products…
> read more
Reinnervate to launch alvetex® in the…
Sedgefield, UK. 11th March 2011. Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, is delighted to announce the upcoming US launch of alvetex®…
> read more
Reinnervate enhances commercial and product development…
Sedgefield, UK. 8th March 2011. Reinnervate, the life sciences company driving the adoption of routine 3D cell culture, is delighted to announce the appointments of Richard Rowling as Commercial Director…
> read more
Alvetex® named in the top ten life…
Sedgefield, UK. 1st December 2010 Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, is proud to announce that alvetex®, its breakthrough…
> read more
Reinnervate partners with LGC for global distribution…
Sedgefield, UK. 29th November 2010. Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, is delighted to announce that it is partnering with LGC Standards…
> read more
Reinnervate launches alvetex®, a breakthrough…
Sedgefield, UK. 22nd November 2010. Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, is very pleased to announce today the first commercial launch…
> read more
Reinnervate gears up for the launch of alvetex®…
Sedgefield, UK. 18th November 2010. Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, today announced the appointment of Classic Industries Europe for…
> read more
Reinnervate completes expansion into new purpose-built…
Sedgefield, UK. 16th November 2010 Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, today announced its expansion into a new purpose-built research…
> read more
Reinnervate to speak at the Cell-based Assays Conference…
reinnervate is pleased to announce that Professor Stefan Przyborski, reinnervate’s founder and Chief Scientific Officer, will be presenting at the third annual conference on Cell-based Assays…
> read more
Reinnervate launches new website with interactive…
Sedgefield, UK. 7th October 2010 reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, today announced the launch of its new, fully interactive website…
> read more
Reinnervate wins Chemistry Innovation / EPSRC Industrial…
Reinnervate has been granted a Chemistry Innovation Knowledge Transfer Network / EPSRC Industrial CASE Award to fund the development of a next-generation Alvetex® scaffold…
> read more
Reinnervate has been accepted as a new member of the…
Reinnervate has been accepted as a new member of the In Vitro Testing Industrial Platform (IVTIP – www.ivtip.org). The Company joins…
> read more
Reinnervate secures £1.8 million of investment to…
Sedgefield, UK. 27th May 2010. Reinnervate, the life sciences company driving the adoption of routine 3D cell culture, today announced that it had successfully raised £1.8 million in new equity…
> read more
Join Our Mail List